Chromosomal region maintenance 1 (CRM1) is associated with an adverse prognosis in glioma. We previously reported that CRM1 inhibition suppressed glioma cell proliferation both in vitro and in vivo. In this study, we investigated the role of CRM1 in the migration and invasion of glioma cells. S109, a novel reversible selective inhibitor of CRM1, was used to treat Human glioma U87 and U251 cells. Cell migration and invasion were evaluated by wound-healing and transwell invasion assays. The results showed that S109 significantly inhibited the migration and invasion of U87 and U251 cells. However, mutation of Cys528 in CRM1 abolished the inhibitory activity of S109 in glioma cells. Furthermore, we found that S109 treatment decreased the expression level and activity of MMP2 and reduced the level of phosphorylated STAT3 but not total STAT3. Therefore, the inhibition of migration and invasion induced by S109 may be associated with the downregulation of MMP2 activity and expression, and inactivation of the STAT3 signaling pathway. These results support our previous conclusion that inhibition of CRM1 is an attractive strategy for the treatment of glioma.
Keywords: Glioma; Invasion; Migration; S109; STAT3/MMP2 signaling.
Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway.Korean J Physiol Pharmacol. 2020 May 1;24(3):193-201. doi: 10.4196/kjpp.2020.24.3.193. Korean J Physiol Pharmacol. 2020. PMID: 32395070 Free PMC article.
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.J Hematol Oncol. 2016 Oct 12;9(1):108. doi: 10.1186/s13045-016-0338-2. J Hematol Oncol. 2016. PMID: 27733172 Free PMC article.
CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.Korean J Physiol Pharmacol. 2016 Mar;20(2):161-8. doi: 10.4196/kjpp.2016.20.2.161. Epub 2016 Feb 23. Korean J Physiol Pharmacol. 2016. PMID: 26937212 Free PMC article.
Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.Cancer Biol Ther. 2015;16(7):1110-8. doi: 10.1080/15384047.2015.1047569. Epub 2015 May 21. Cancer Biol Ther. 2015. PMID: 25996664 Free PMC article.
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.J Ovarian Res. 2015 Jun 10;8:35. doi: 10.1186/s13048-015-0166-y. J Ovarian Res. 2015. PMID: 26055813 Free PMC article.